Radioembolization with 166Ho microspheres induced a tumor response with an acceptable toxicity profile in patients with liver metastases.
Featured product: QuiremSpheres® Microspheres
Main Findings HEPAR 2 study:
38 Patients with unresectable liver metastases of any primary origin, who were unable to undergo systemic treatment were eligible. The main primary malignancies were colorectal (61%), breast (11%), cholangiocarcinoma (11%), neuroendocrine tumor (5%) and uveal melanoma (5%).
Single radioembolization with 166Ho polylactic microspheres, administered via the hepatic artery. The projected average absorbed dose was 60 Gy to the liver (equal to 3.8 GBq/kg liver tissue).
Response 3 months after 166Ho radioembolization
Number of patients (percentage of total).
* Not evaluable and/or missing patients classified as progressive disease
Study results have been published in PhD thesis of J.F. Prince; ISBN 978-90-393-6489-5; 2016. Publication in peer-reviewed journal is expected soon.
ClinicalTrials.gov Identifier: NCT01612325
This is HCP only content
website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.
Essential cookies to ensure the website functions well.
Cookies to help us measure the general use of our website.
Cookies that save personal information while browsing.